Sensorion Announces the Completion of Patient Inclusion in Phase 2a Clinical Trial of SENS-401 for R

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News:Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, today announces the recruitment of the last patien...

Related Keywords

Institut Pasteur ,Nicolas Entz ,Noemie Djokovic ,Pierre Louis Germain ,International Media Relations ,Regulatory News ,Cochlear Limited ,Chief Medical Officer ,Cisplatin Induced ,Orphan Drug Designation ,Cisplatin Induced Ototoxicity ,Sudden Sensorineural Hearing Loss ,Investor Relations ,Communications Associate ,Louis Germain ,